Bjerg
Anders Sylvester Bjerg, Brande DK
Patent application number | Description | Published |
---|---|---|
20150061295 | WIND TURBINE, A GENERATOR, A ROTOR HOUSING, AND A METHOD FOR MAKING THE ROTOR HOUSING - Described is a wind turbine, a generator and a rotor housing for a generator with an external rotor, the rotor housing comprising a support structure, wherein the support structure is cylindrical shaped, a cone and a ring. The ring and the cone are attached together at an inner side of the cone in a horizontal plane, forming a front part of the rotor housing. The support structure is attached to the cone at a front end of the support structure, forming a side part of the rotor housing, and the support structure is formed out of segmented support structure parts. Also disclosed is the method for making the rotor housing. | 03-05-2015 |
Lise Norkjaer Bjerg, Hellerup DK
Patent application number | Description | Published |
---|---|---|
20140343413 | FORMULATION OF SOLID NANO-SIZED PARTICLES IN A GEL-FORMING SYSTEM - The present invention relates to novel formulations comprising a plurality of nano-sized solid particles and a gel-forming system, useful, e.g. for imaging of the body of a mammal. Also described are kits comprising such formulations and imaging methods utilizing such formulations or kits. | 11-20-2014 |
Thomas Bjerg, Copenhagen Oe DK
Patent application number | Description | Published |
---|---|---|
20160000884 | Liquid Factor VIII Formulations - The invention is directed to a liquid, aqueous formulation of coagulation Factor VIII, comprising a Factor VIII molecule, a calcium salt in a concentration of more than 10 mM, and a saccharide and/or polyol in a concentration of at least 100 mM, wherein the formulation has a pH from 5.5-7.5. The invention furthermore provides a method for optimising a liquid formulation of coagulation Factor VIII, the method comprising the steps of: (i) Providing one or more liquid formulations comprising Factor VIII to be tested; (ii) Adding a protein denaturant to said liquid formulations, and incubating the resulting solutions for a predetermined period of time; (iii) Analysing the incubated solutions of (ii) for the presence of dissociated Factor VIII; and (iv) Selecting one or more formulation(s) having a desired low level of dissociated Factor VIII. | 01-07-2016 |